Laufer SA - Search Results

1

Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors.

Hoyt KW, Urul DA, Ogboo BC, Wittlinger F, Laufer SA, Schaefer EM, May EW, Heppner DE. Hoyt KW, et al. Among authors: laufer sa. J Med Chem. 2024 Jan 11;67(1):2-16. doi: 10.1021/acs.jmedchem.3c01502. Epub 2023 Dec 22. J Med Chem. 2024. PMID: 38134304 Review.

2

From imidazoles to pyrimidines: new inhibitors of cytokine release.

Laufer SA, Wagner GK. Laufer SA, et al. J Med Chem. 2002 Jun 20;45(13):2733-40. doi: 10.1021/jm011098a. J Med Chem. 2002. PMID: 12061876

3

Imidazole inhibitors of cytokine release: probing substituents in the 2 position.

Laufer SA, Striegel HG, Wagner GK. Laufer SA, et al. J Med Chem. 2002 Oct 10;45(21):4695-705. doi: 10.1021/jm020873z. J Med Chem. 2002. PMID: 12361396

4

Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.

Laufer SA, Domeyer DM, Scior TR, Albrecht W, Hauser DR. Laufer SA, et al. J Med Chem. 2005 Feb 10;48(3):710-22. doi: 10.1021/jm0408767. J Med Chem. 2005. PMID: 15689155

5

New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase.

Peifer C, Wagner G, Laufer S. Peifer C, et al. Curr Top Med Chem. 2006;6(2):113-49. doi: 10.2174/156802606775270323. Curr Top Med Chem. 2006. PMID: 16454763 Review.

6

From five- to six-membered rings: 3,4-diarylquinolinone as lead for novel p38MAP kinase inhibitors.

Peifer C, Kinkel K, Abadleh M, Schollmeyer D, Laufer S. Peifer C, et al. J Med Chem. 2007 Mar 22;50(6):1213-21. doi: 10.1021/jm061097o. Epub 2007 Feb 27. J Med Chem. 2007. PMID: 17323937

7

Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors.

Hauser DR, Scior T, Domeyer DM, Kammerer B, Laufer SA. Hauser DR, et al. Among authors: laufer sa. J Med Chem. 2007 May 3;50(9):2060-6. doi: 10.1021/jm061061w. Epub 2007 Apr 6. J Med Chem. 2007. PMID: 17411025

8

Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors.

Peifer C, Selig R, Kinkel K, Ott D, Totzke F, Schächtele C, Heidenreich R, Röcken M, Schollmeyer D, Laufer S. Peifer C, et al. J Med Chem. 2008 Jul 10;51(13):3814-24. doi: 10.1021/jm8001185. Epub 2008 Jun 5. J Med Chem. 2008. PMID: 18529047

9

Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.

Laufer SA, Hauser DR, Domeyer DM, Kinkel K, Liedtke AJ. Laufer SA, et al. J Med Chem. 2008 Jul 24;51(14):4122-49. doi: 10.1021/jm701529q. Epub 2008 Jun 26. J Med Chem. 2008. PMID: 18578517

10

Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical properties.

Karcher SC, Laufer SA. Karcher SC, et al. Among authors: laufer sa. J Med Chem. 2009 Mar 26;52(6):1778-82. doi: 10.1021/jm801291f. J Med Chem. 2009. PMID: 19253982

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

253 results

Search Page

Filters